Literature DB >> 15966895

Over-expression of Aurora-A targets cytoplasmic polyadenylation element binding protein and promotes mRNA polyadenylation of Cdk1 and cyclin B1.

Takashi Sasayama1, Tomotoshi Marumoto, Naoko Kunitoku, Dongwei Zhang, Norihiko Tamaki, Eiji Kohmura, Hideyuki Saya, Toru Hirota.   

Abstract

Aurora-A is a centrosomal serine-threonine kinase that regulates mitosis. Over-expression of Aurora-A has been found in a wide range of tumors and has been implicated in oncogenic transformation. However, how Aurora-A over-expression contributes to promotion of carcinogenesis remains elusive. Immunohistochemical analysis of breast tumors revealed that over-expressed Aurora-A is not restricted to the centrosomes but is also found in the cytoplasm. This over-expressed Aurora-A appeared to be phosphorylated on Thr288, which is known to be required for its enzymatic activation. In analogy to Aurora-A's role in oocyte maturation and the early embryonic cell cycle, here we investigated whether ectopically over-expressed Aurora-A can similarly stimulate polyadenylation of mRNA in human somatic cultured cells by interacting with a human ortholog of cytoplasmic polyadenylation element binding protein, h-CPEB. In vitro experiments revealed that Aurora-A binds directly to, and phosphorylates, h-CPEB. We found that polyadenylation of mRNA tails of cyclin B1 and Cdk1 was synergistically stimulated when Aurora-A and h-CPEB were over-expressed, and they were further promoted in the presence of an Aurora-A activator Ajuba. Our results suggest a function of ectopically over-expressed Aurora-A that might be relevant for carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15966895     DOI: 10.1111/j.1365-2443.2005.00870.x

Source DB:  PubMed          Journal:  Genes Cells        ISSN: 1356-9597            Impact factor:   1.891


  17 in total

1.  Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas.

Authors:  Norman L Lehman; James P O'Donnell; Lisa J Whiteley; Robert T Stapp; Trang D Lehman; Kathleen M Roszka; Lonni R Schultz; Caitlin J Williams; Tom Mikkelsen; Stephen L Brown; Jeffrey A Ecsedy; Laila M Poisson
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

Review 2.  Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer.

Authors:  Steven L Warner; Bret J Stephens; Daniel D Von Hoff
Journal:  Curr Oncol Rep       Date:  2008-03       Impact factor: 5.075

Review 3.  The Centrosome, a Multitalented Renaissance Organelle.

Authors:  Anastassiia Vertii; Heidi Hehnly; Stephen Doxsey
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-12-01       Impact factor: 10.005

4.  Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma.

Authors:  C Kurokawa; H Geekiyanage; C Allen; I Iankov; M Schroeder; B Carlson; K Bakken; J Sarkaria; J A Ecsedy; A D'Assoro; B Friday; E Galanis
Journal:  J Neurooncol       Date:  2016-11-05       Impact factor: 4.130

5.  TPX2 overexpression in medullary thyroid carcinoma mediates TT cell proliferation.

Authors:  Xiaolin Yang; Geling Liu; Hongzhen Xiao; Fang Yu; Xiuxiu Xiang; Yifang Lu; Weijuan Li; Xiuling Liu; Sha Li; Yanping Shi
Journal:  Pathol Oncol Res       Date:  2014-02-01       Impact factor: 3.201

6.  Bioactive tanshinones in Salvia miltiorrhiza inhibit the growth of prostate cancer cells in vitro and in mice.

Authors:  Yi Gong; Yanli Li; Yin Lu; Linglin Li; Hamid Abdolmaleky; George L Blackburn; Jin-Rong Zhou
Journal:  Int J Cancer       Date:  2010-11-03       Impact factor: 7.396

7.  Aurora A, mitotic entry, and spindle bipolarity.

Authors:  Quentin Liu; Joan V Ruderman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-31       Impact factor: 11.205

8.  Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma.

Authors:  James R Van Brocklyn; Jeffrey Wojton; Walter H Meisen; David A Kellough; Jeffery A Ecsedy; Balveen Kaur; Norman L Lehman
Journal:  Cancer Res       Date:  2014-08-08       Impact factor: 12.701

Review 9.  Aurora A kinase (AURKA) in normal and pathological cell division.

Authors:  Anna S Nikonova; Igor Astsaturov; Ilya G Serebriiskii; Roland L Dunbrack; Erica A Golemis
Journal:  Cell Mol Life Sci       Date:  2012-08-03       Impact factor: 9.261

10.  The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation.

Authors:  Xin Hong; James P O'Donnell; Clarence R Salazar; James R Van Brocklyn; Kahlil D Barnett; Dennis K Pearl; Ana C deCarvalho; Jeffrey A Ecsedy; Stephen L Brown; Tom Mikkelsen; Norman L Lehman
Journal:  Cancer Chemother Pharmacol       Date:  2014-03-14       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.